Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Sangamo Therapeutics (NQ: SGMO )

0.8038 +0.1038 (+14.83%)
Streaming Delayed Price Updated: 12:07 PM EDT, Jul 31, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Sangamo Therapeutics

< Previous 1 2 3 Next >
There's a Lot of Upside For Emerging Gene-Editing Companies
These four gene-editing companies are brand new, with very high upside potential. The industry itself is still emerging, which means more growth could come. 
Via MarketBeat
Sangamo Therapeutics Announces Fourth Quarter and Full Year 2022 Conference Call and Webcast
From Sangamo Therapeutics, Inc.
Via Business Wire
Sangamo Therapeutics Reports Recent Business Highlights and Third Quarter 2022 Financial Results
From Sangamo Therapeutics, Inc.
Via Business Wire
Sangamo Therapeutics Announces Third Quarter 2022 Conference Call and Webcast
From Sangamo Therapeutics, Inc.
Via Business Wire
Sangamo Therapeutics Announces Updated Preliminary Phase 1/2 Data in Fabry Disease Showing Continued Tolerability and Sustained Elevated α-Gal A Enzyme Activity in Nine Patients
From Sangamo Therapeutics, Inc.
Via Business Wire
Sangamo Therapeutics Announces Updated Preliminary Phase 1/2 Data in Fabry Disease Clinical Study Showing Continued Tolerability and Sustained Elevated α-gal A Enzyme Activity in Five Longest Treated Patients
From Sangamo Therapeutics, Inc.
Via Business Wire
Sangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2022 Financial Results
From Sangamo Therapeutics, Inc.
Via Business Wire
Sangamo Therapeutics Announces Second Quarter 2022 Conference Call and Webcast
From Sangamo Therapeutics, Inc.
Via Business Wire
European Orphan Medicinal Product Designation Granted to Sangamo Therapeutics Investigational CAR-Treg Cell Therapy TX200 for Solid Organ Transplantation
From Sangamo Therapeutics, Inc.
Via Business Wire
Sangamo Therapeutics Announces Participation at Upcoming Investor Conferences
From Sangamo Therapeutics, Inc.
Via Business Wire
Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2022 Financial Results
From Sangamo Therapeutics, Inc.
Via Business Wire
Sangamo Therapeutics to Present Data From Its Next-Generation Technologies at 2022 Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
From Sangamo Therapeutics, Inc.
Via Business Wire
Sangamo Therapeutics Announces First Quarter 2022 Conference Call and Webcast
From Sangamo Therapeutics, Inc.
Via Business Wire
Sangamo Therapeutics Announces Participation at Upcoming Investor Conferences
From Sangamo Therapeutics, Inc.
Via Business Wire
Sangamo Therapeutics Announces Dosing of First Patient in Phase 1/2 Clinical Study of Investigational CAR-Treg Cell Therapy TX200 in Kidney Transplantation
From Sangamo Therapeutics, Inc.
Via Business Wire
Sangamo Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Business Highlights
From Sangamo Therapeutics, Inc.
Via Business Wire
Sangamo Therapeutics Announces Fourth Quarter and Full Year 2021 Conference Call and Webcast
From Sangamo Therapeutics, Inc.
Via Business Wire
Sangamo Therapeutics Announces Updated Preliminary Phase 1/2 Data Showing Tolerability and Sustained Elevated α-Gal A Enzyme Activity in Patients With Fabry Disease
From Sangamo Therapeutics, Inc.
Via Business Wire
Sangamo Announces Transition of SAR445136 Sickle Cell Disease Program From Sanofi to Sangamo
From Sangamo Therapeutics, Inc.
Via Business Wire
Sangamo Therapeutics Announces Participation at H.C. Wainwright BIOCONNECT Virtual Conference
From Sangamo Therapeutics, Inc.
Via Business Wire
Pfizer and Sangamo Announce Updated Phase 1/2 Results Showing Sustained Bleeding Control in Highest Dose Cohort Through Two Years Following Hemophilia A Gene Therapy
From Sangamo Therapeutics, Inc.
Via Business Wire
Sangamo Therapeutics Announces Updated Preliminary SAR445136 Phase 1/2 Proof-of-Concept Data Showing Tolerability and Sustained Effects in Sickle Cell Disease
From Sangamo Therapeutics, Inc.
Via Business Wire
Sangamo Therapeutics Announces Participation at Upcoming Investor Conferences
From Sangamo Therapeutics, Inc.
Via Business Wire
Sangamo Therapeutics Reports Recent Business and Clinical Highlights and Third Quarter 2021 Financial Results
From Sangamo Therapeutics, Inc.
Via Business Wire
Sangamo Therapeutics Announces Preliminary Phase 1/2 Data Showing Tolerability and Sustained Elevated α-Gal A Enzyme Activity in Patients With Fabry Disease
From Sangamo Therapeutics, Inc.
Via Business Wire
Sangamo Therapeutics Announces Third Quarter 2021 Conference Call and Webcast
From Sangamo Therapeutics, Inc.
Via Business Wire
Sangamo Therapeutics Announces Participation at Upcoming Investor Conferences
From Sangamo Therapeutics, Inc.
Via Business Wire
Sangamo Therapeutics Announces Participation at 2021 Wedbush PacGrow Healthcare Conference
From Sangamo Therapeutics, Inc.
Via Business Wire
Sangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2021 Financial Results
From Sangamo Therapeutics, Inc.
Via Business Wire
Sangamo Therapeutics Announces Second Quarter 2021 Conference Call and Webcast
From Sangamo Therapeutics, Inc.
Via Business Wire
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.